← Leaderboards
Madhavika Niroshini Serasinghe
Icahn School Of Medicine At Mount Sinai
$576,000
Attributed
$576,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $192K · FY2017–19$200K$150K$100K$50K$0
'17
'18
'19
Funding mix
By agency
NIH$576,000 · 1
By mechanism
K22$576,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Emma Guttman$8,500,791
- Jerry Edward Chipuk$8,893,226
- Jennifer M Reckrey$1,053,162
- Mone Zaidi$25,912,145
- William Paul Duprex$23,556,651
Others in their field
Other Emerging Leaders on “Drug Discovery”
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- John Damon Chodera · Sloan-Kettering Inst Can Research$64,994,606
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Gary Kobinger · University Of Texas Med Br Galveston$41,631,815
Research focus
Drug DiscoveryAssay DevelopmentBaseAntibodiesBench To BedsideBindingBiochemicalBiochemistryBasic ScienceAnticancer ResearchCancer CellCareerCareer DevelopmentCell DeathCellsCellular BiologyClinically RelevantCollaborationsCrystallizationBiological MarkersBiologyDockingDrug DevelopmentEarly Diagnosis
Grant awards (3)
Mechanistic, prognostic, and therapeutic impact of the mitochondrial fission GTPase DRP1 in melanoma$192,000
K22 · FY2019 · CA · contact PI
Mechanistic, prognostic, and therapeutic impact of the mitochondrial fission GTPase DRP1 in melanoma$192,000
K22 · FY2018 · CA · contact PI
Mechanistic, prognostic, and therapeutic impact of the mitochondrial fission GTPase DRP1 in melanoma$192,000
K22 · FY2017 · CA · contact PI